Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Medicine
FDA Grants Accelerated Approval to Zongertinib for HER2-Mutant Lung Cancer
The FDA granted accelerated approval to zongertinib for adults with unresectable or metastatic non-squamous NSCLC with HER2 tyrosine kinase domain activating mutations.
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
The FDA granted accelerated approval to zongertinib on 26 February for an expanded indication in non-squamous non-small cell lung cancer.
The indication covers adults with unresectable or metastatic disease whose tumors have HER2 or ERBB2 tyrosine kinase domain activating mutations detected by an FDA-authorized test.
The FDA also described the approval as part of the Commissioner’s National Priority Voucher pilot program, with the application filed on 13 January 2026.
Sourcing note: Indication and programme details are from FDA. Accelerated approval means confirmatory evidence requirements remain important.
Why It Matters
The approval is another example of lung cancer treatment becoming more molecularly defined. It also shows FDA using priority-review experiments to compress timelines for selected drugs while still relying on follow-up evidence.
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDAZongertinibHER2NSCLCAccelerated Approval